IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

131Citations
Citations of this article
115Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. We show that IRAK1 overexpression confers TNBC growth advantage through NF-B-related cytokine secretion and metastatic TNBC cells exhibit gain of IRAK1 dependency, resulting in high susceptibility to genetic and pharmacologic inhibition of IRAK1. Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment. Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway. Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.

Cite

CITATION STYLE

APA

Wee, Z. N., Yatim, S. M. J. M., Kohlbauer, V. K., Feng, M., Goh, J. Y., Yi, B., … Yu, Q. (2015). IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 6. https://doi.org/10.1038/ncomms9746

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free